Oncolytics Biotech Statistics
Share Statistics
Oncolytics Biotech has 86.42M
shares outstanding. The number of shares has increased by 13.93%
in one year.
| Shares Outstanding | 86.42M |
| Shares Change (YoY) | 13.93% |
| Shares Change (QoQ) | 12.13% |
| Owned by Institutions (%) | 1.73% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 108,715 |
| FTD / Avg. Volume | 31.17% |
Short Selling Information
The latest short interest is 2.69M, so 3.11% of the outstanding
shares have been sold short.
| Short Interest | 2.69M |
| Short % of Shares Out | 3.11% |
| Short % of Float | 3.23% |
| Short Ratio (days to cover) | 5.78 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -1.33 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Oncolytics Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.82,
with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.82 |
| Quick Ratio | 2.82 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-991,142.86 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 97K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -52.99% in the
last 52 weeks. The beta is 1.55, so Oncolytics Biotech's
price volatility has been higher than the market average.
| Beta | 1.55 |
| 52-Week Price Change | -52.99% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 45 |
| Average Volume (20 Days) | 348,755 |
Income Statement
| Revenue | n/a |
| Gross Profit | -403K |
| Operating Income | -33.79M |
| Net Income | -27.75M |
| EBITDA | -33.71M |
| EBIT | -33.79M |
| Earnings Per Share (EPS) | -0.41 |
Full Income StatementBalance Sheet
The company has 15.94M in cash and 1.06M in
debt, giving a net cash position of 14.88M.
| Cash & Cash Equivalents | 15.94M |
| Total Debt | 1.06M |
| Net Cash | 14.88M |
| Retained Earnings | -477.71M |
| Total Assets | 20.19M |
| Working Capital | 12.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -26.97M
and capital expenditures -239K, giving a free cash flow of -27.2M.
| Operating Cash Flow | -26.97M |
| Capital Expenditures | -239K |
| Free Cash Flow | -27.2M |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
